LEP and early-onset autosomal dominant Alzheimer disease: For instance, trials like NCT00690235, which focused on schizophrenia and medication-induced weight gain, and NCT03560960, which was aimed at Alzheimer’s disease and mild cognitive impairment, highlight the broader implications of improving leptin sensitivity in the context of brain dysfunction (Table 1).